Kenneth Offit

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5962809/publications.pdf

Version: 2024-02-01

381 papers	39,831 citations	1981 104 h-index	4035 182 g-index
395 all docs	395 docs citations	395 times ranked	37911 citing authors

#	Article	IF	Citations
1	Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial. BMJ Open, 2022, 8, e021876.	0.8	22
2	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
3	Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. JCO Oncology Practice, 2022, 18, 201-209.	1.4	34
4	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371.	1.1	7
5	Inherited TP53 Variants and Risk of Prostate Cancer. European Urology, 2022, 81, 243-250.	0.9	40
6	Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. Genetics in Medicine, 2022, 24, 564-575.	1.1	8
7	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
8	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	2.2	15
9	Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. Genetics in Medicine, 2022, 24, 1187-1195.	1.1	7
10	Cancer-Causative Mutations Occurring in Early Embryogenesis. Cancer Discovery, 2022, 12, 949-957.	7.7	21
11	SNPs at SMG7 associated with time from biochemical recurrence to prostate cancer death. Cancer Epidemiology Biomarkers and Prevention, 2022, , .	1.1	1
12	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology, 2021, 160, 1164-1178.e6.	0.6	36
13	Characterization and Clinical Outcomes of DNA Mismatch Repairâ€“deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	3.2	23
14	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. Clinical Cancer Research, 2021, 27, 1997-2010.	3.2	15
15	Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. American Journal of Clinical Nutrition, 2021, 113, 1490-1502.	2.2	27
16	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
17	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
18	Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 2021, 70, 1325-1334.	6.1	44

#	Article	IF	Citations
19	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	5.7	74
20	Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	1.5	10
21	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Human Molecular Genetics, 2021, 30, 1142-1153.	1.4	2
22	Response to Li and Hopper. American Journal of Human Genetics, 2021, 108, 527-529.	2.6	5
23	The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care. Genetics in Medicine, 2021, 23, 1086-1094.	1.1	18
24	Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1336-1348.	1.1	15
25	Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia. Neuron, 2021, 109, 1465-1478.e4.	3.8	21
26	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
27	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753.	2.8	15
28	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	2.6	6
29	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. Journal of the National Cancer Institute, 2021, , .	3.0	6
30	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genetics in Medicine, 2021, 23, 2105-2113.	1.1	29
31	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	3.0	66
32	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	0.8	83
33	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	2.9	9
34	Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. Gynecologic Oncology, 2021, 162, 506-516.	0.6	39
35	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102.	2.3	498
36	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. Npj Breast Cancer, 2021, 7, 135.	2.3	9

#	Article	IF	Citations
37	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. European Urology Oncology, 2021, 4, 993-1000.	2.6	16
38	Clonal hematopoiesis is associated with risk of severe Covid-19. Nature Communications, 2021, 12, 5975.	5.8	81
39	Facilitated cascade testing (FaCT): a randomized controlled trial. International Journal of Gynecological Cancer, 2021, 31, 779-783.	1.2	6
40	The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics, 2021, 53, 1577-1585.	9.4	44
41	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
42	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. Human Molecular Genetics, 2020, 29, 70-79.	1.4	17
43	Genetic Factors. , 2020, , 180-208.e11.		4
44	Fumarate hydrataseFHc.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. Human Mutation, 2020, 41, 103-109.	1.1	25
45	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
46	Cumulative Burden of Colorectal Cancerâ€"Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12.	0.6	110
47	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. Gastroenterology, 2020, 158, 1300-1312.e20.	0.6	90
48	Identification of Novel Loci and New Risk Variant in Known Loci for Colorectal Cancer Risk in East Asians. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 477-486.	1.1	25
49	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
50	Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial. Genetics in Medicine, 2020, 22, 727-735.	1.1	34
51	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. Journal of Clinical Oncology, 2020, 38, 406-414.	0.8	60
52	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
53	A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.4	32
54	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. American Journal of Human Genetics, 2020, 107, 432-444.	2.6	124

#	Article	IF	Citations
55	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	9.4	367
56	Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses. BMC Medicine, 2020, 18, 229.	2.3	28
57	Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. Journal of Thoracic Oncology, 2020, 15, 1871-1879.	0.5	24
58	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	1.5	9
59	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Medicine, 2020, 18, 396.	2.3	76
60	Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis. Human Genetics and Genomics Advances, 2020, 1, 100010.	1.0	3
61	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
62	Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 2020, 11, 2220.	5.8	31
63	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	1.6	2
64	Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel <i>BRCA1/2</i> Genetic Risk Modifier Test. Public Health Genomics, 2020, 23, 6-19.	0.6	7
65	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
66	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
67	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. Journal of Clinical Oncology, 2020, 38, 1398-1408.	0.8	60
68	Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling. Journal of Clinical Oncology, 2020, 38, 1389-1397.	0.8	48
69	11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. Cancer, 2020, 126, 3114-3121.	2.0	23
70	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nature Communications, 2020, 11, 597.	5.8	193
71	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	2.3	314
72	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	3.0	129

#	Article	IF	Citations
73	Genetic overlap between autoimmune diseases and nonâ€Hodgkin lymphoma subtypes. Genetic Epidemiology, 2019, 43, 844-863.	0.6	28
74	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. European Urology, 2019, 76, 754-764.	0.9	80
75	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	13.7	295
76	Pathogenic Loss-of-Function Germline TERT Mutations in Patients With Solid Tumors. JCO Precision Oncology, 2019, 3, 1-5.	1.5	2
77	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
78	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	1.6	5
79	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
80	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
81	BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	1.1	26
82	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
83	CHEK2 Alleles Predispose to Renal Cancer in Polandâ€”In Reply. JAMA Oncology, 2019, 5, 576.	3.4	1
84	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	0.8	397
85	Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. Human Genetics, 2019, 138, 307-326.	1.8	44
86	Toward automation of germline variant curation in clinical cancer genetics. Genetics in Medicine, 2019, 21, 2116-2125.	1.1	27
87	Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. BMJ Open, 2019, 9, e031092.	0.8	10
88	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	1.5	7
89	Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. Cancer Prevention Research, 2019, 12, 599-608.	0.7	6
90	Germline deletion of ETV6 in familial acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1039-1046.	2.5	21

#	Article	IF	Citations
91	A case for expert curation: an overview of cancer curation in the Clinical Genome Resource (ClinGen). Journal of Physical Education and Sports Management, 2019, 5, a004739.	0.5	14
92	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
93	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
94	Determining the clinical validity of hereditary colorectal cancer and polyposis susceptibility genes using the Clinical Genome Resource Clinical Validity Framework. Genetics in Medicine, 2019, 21, 1507-1516.	1.1	19
95	Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. Genetics in Medicine, 2019, 21, 1497-1506.	1.1	52
96	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	9.4	377
97	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. Frontiers in Oncology, 2019, 9, 1539.	1.3	6
98	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genetics in Medicine, 2018, 20, 1324-1327.	1.1	31
99	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074.	3.0	170
100	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
101	The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results. European Journal of Human Genetics, 2018, 26, 984-995.	1.4	42
102	High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. Human Genetics, 2018, 137, 343-355.	1.8	24
103	Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Research, 2018, 78, 2747-2759.	0.4	56
104	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752.	1.5	148
105	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for WaldenstrÃ¶m macroglobulinemia. Nature Communications, 2018, 9, 4182.	5.8	15
106	Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes. Human Mutation, 2018, 39, 1542-1552.	1.1	40
107	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 2018, 4, 1228.	3.4	132
108	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54

#	Article	IF	Citations
109	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Research, 2018, 78, 4086-4096.	0.4	34
110	Germline SDHA mutations in children and adults with cancer. Journal of Physical Education and Sports Management, 2018, 4, a002584.	0.5	33
111	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. Journal of Clinical Oncology, 2018, 36, 1504-1504.	0.8	2
112	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genetics, 2018, 14, e1007111.	1.5	30
113	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. European Journal of Human Genetics, 2017, 25, 432-438.	1.4	26
114	Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. Breast Cancer Research and Treatment, 2017, 162, 297-306.	1.1	16
115	Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. Cancer, 2017, 123, 2452-2458.	2.0	12
116	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14175.	5.8	75
117	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 9-20.	2.3	408
118	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22.	2.3	108
119	Multigene Testing for Hereditary Cancer: When, Why, and How. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 741-743.	2.3	7
120	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
121	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
122	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	3.8	366
123	Integrative clinical genomics of metastatic cancer. Nature, 2017, 548, 297-303.	13.7	685
124	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Science and Medicine, 2017, 4, e000187.	1.1	15
125	Germline BRCA2 mutations detected in pediatric sequencing studies impact parentsâ€™ evaluation and care. Journal of Physical Education and Sports Management, 2017, 3, a001925.	0.5	17
126	Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Medical Genomics, 2017, 10, 33.	0.7	111

#	Article	IF	Citations
127	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
128	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 126-135.	1.1	278
129	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	242
130	Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers. JCO Precision Oncology, 2017, 1, 1-13.	1.5	6
131	Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. Journal of Oncology Practice, 2017, 13, e590-e601.	2.5	27
132	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	286
133	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. Journal of Clinical Oncology, 2017, 35, 1262-1263.	0.8	1
134	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
135	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
136	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncology, 2016, 2, 1434.	3.4	189
137	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	13.9	1,205
138	Twentyâ€oneâ€“gene recurrence score assay in <scp>BRCA</scp>â€associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer, 2016, 122, 1178-1184.	2.0	42
139	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 153-162.	2.3	153
140	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
141	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 2016, 34, 2141-2147.	0.8	204
142	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. American Journal of Human Genetics, 2016, 98, 801-817.	2.6	113
143	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
144	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. Journal of Clinical Oncology, 2016, 34, 4071-4078.	0.8	147

#	Article	IF	Citations
145	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discovery, 2016, 6, 1267-1275.	7.7	41
146	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
147	The future of clinical cancer genomics. Seminars in Oncology, 2016, 43, 615-622.	0.8	23
148	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
149	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
150	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. Breast Cancer Research and Treatment, 2016, 160, 447-456.	1.1	16
151	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933.	5.8	94
152	Age- and Tumor Subtypeâ€“Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	0.8	152
153	Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews Clinical Oncology, 2016, 13, 581-588.	12.5	258
154	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology, 2016, 2, 104.	3.4	270
155	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility, 2016, 105, 781-785.	0.5	38
156	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Human Molecular Genetics, 2016, 25, 1663-1676.	1.4	52
157	Genomic Biomarkers for Breast Cancer Risk. Advances in Experimental Medicine and Biology, 2016, 882, 1-32.	0.8	42
158	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
159	Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 238.e1-238.e7.	0.8	20
160	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	3.0	77
161	Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. Briefings in Bioinformatics, 2016, 17, 672-677.	3.2	6
162	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18

#	Article	IF	Citations
163	Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. Journal of Clinical Oncology, 2016, 34, e61-e67.	0.8	6
164	Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants.. Journal of Clinical Oncology, 2016, 34, 1518-1518.	0.8	3
165	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
166	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	3.0	152
167	Identification of germline genetic mutations in patients with pancreatic cancer. Cancer, 2015, 121, 4382-4388.	2.0	167
168	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
169	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. PLoS Genetics, 2015, 11, e1005262.	1.5	128
170	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nature Communications, 2015, 6, 5751.	5.8	58
171	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	3.0	428
172	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	1.4	40
173	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
174	FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
175	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
176	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
177	Tissue-Specific Enrichment of Lymphoma Risk Loci in Regulatory Elements. PLoS ONE, 2015, 10, e0139360.	1.1	5
178	Genome-wide analysis of the role of copy-number variation in pancreatic cancer risk. Frontiers in Genetics, 2014, 5, 29.	1.1	13
179	Clinical features and management of em BRCA1 em and em BRCA2- em associated prostate cancer. Frontiers in Bioscience - Elite, 2014, E6, 15-30.	0.9	21
180	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47

#	Article	IF	Citations
181	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
182	Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention. Science, 2014, 343, 1466-1470.	6.0	300
183	A decade of discovery in cancer genomics. Nature Reviews Clinical Oncology, 2014, 11, 632-634.	12.5	17
184	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	9.4	147
185	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471.	2.6	96
186	Cancer Genomics and Inherited Risk. Journal of Clinical Oncology, 2014, 32, 687-698.	0.8	121
187	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nature Communications, 2014, 5, 4835.	5.8	156
188	Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. Breast Cancer Research and Treatment, 2014, 145, 625-634.	1.1	11
189	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1326-1338.	2.3	119
190	Genetic Variation in DNA Repair Pathways and Risk of Non-Hodgkin's Lymphoma. PLoS ONE, 2014, 9, e101685.	1.1	19
191	Genetic Factors. , 2014, , 169-187.e7.		4
192	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Research, 2013, 15, 402.	2.2	36
193	Revealing the Incidentalome When Targeting the Tumor Genome. JAMA - Journal of the American Medical Association, 2013, 310, 795.	3.8	60
194	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	9.4	270
195	Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. Genetics in Medicine, 2013, 15, 721-728.	1.1	40
196	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
197	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 868-876.	9.4	179
198	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. Breast Cancer Research and Treatment, 2013, 138, 273-279.	1.1	31

#	Article	IF	Citations
199	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	1.5	105
200	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
201	Susceptibility Loci Associated with Specific and Shared Subtypes of Lymphoid Malignancies. PLoS Genetics, 2013, 9, e1003220.	1.5	44
202	Evidence of Geneâ€“Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284.	1.5	136
203	Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?. Journal of Clinical Oncology, 2013, 31, 1267-1270.	0.8	217
204	Risk of metachronous breast cancer after BRCA mutationâ€“associated ovarian cancer. Cancer, 2013, 119, 1344-1348.	2.0	58
205	Gene Patents and Personalized Cancer Care: Impact of the Myriad Case on Clinical Oncology. Journal of Clinical Oncology, 2013, 31, 2743-2748.	0.8	60
206	Translating Genomics in Cancer Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1343-1353.	2.3	63
207	Genome-wide association studies of cancer predisposition. , 2013, , 10-20.		1
208	Assessment of SLX4 Mutations in Hereditary Breast Cancers. PLoS ONE, 2013, 8, e66961.	1.1	37
209	Risks to Relatives in Genomic Research: A Duty to Warn?. American Journal of Bioethics, 2012, 12, 12-14.	0.5	19
210	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	1.1	23
211	Heterozygous Mutations in DNA Repair Genes and Hereditary Breast Cancer: A Question of Power. PLoS Genetics, 2012, 8, e1003008.	1.5	13
212	Association of aHOXB13Variant with Breast Cancer. New England Journal of Medicine, 2012, 367, 480-481.	13.9	21
213	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
214	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
215	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 136, 295-302.	1.1	4
216	Rare variants in XRCC2 as breast cancer susceptibility alleles: TableÂ1. Journal of Medical Genetics, 2012, 49, 618-620.	1.5	49

#	Article	IF	Citations
217	Rare De Novo Germline Copy-Number Variation in Testicular Cancer. American Journal of Human Genetics, 2012, 91, 379-383.	2.6	21
218	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	1.1	11
219	Improved survival for BRCA2â€associated serous ovarian cancer compared with both BRCAâ€negative and BRCA1â€associated serous ovarian cancer. Cancer, 2012, 118, 3703-3709.	2.0	72
220	Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations. Cancer, 2012, 118, 6270-6277.	2.0	30
221	Y chromosome haplogroups and prostate cancer in populations of European and Ashkenazi Jewish ancestry. Human Genetics, 2012, 131, 1173-1185.	1.8	14
222	The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 132, 1119-1126.	1.1	8
223	Systematic Immunohistochemistry Screening for Lynch Syndrome in Early Age-of-Onset Colorectal Cancer Patients Undergoing Surgical Resection. Journal of the American College of Surgeons, 2012, 214, 61-67.	0.2	32
224	GermlineBRCAmutation does not prevent response to taxaneâ€based therapy for the treatment of castrationâ€resistant prostate cancer. BJU International, 2012, 109, 713-719.	1.3	40
225	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
226	Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer, 2012, 118, 493-499.	2.0	83
227	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
228	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	1.1	51
229	Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genetics, 2011, 43, 1018-1021.	9.4	662
230	Germline PALB2 mutation analysis in breast-pancreas cancer families. Journal of Medical Genetics, 2011, 48, 523-525.	1.5	28
231	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	2.2	71
232	Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism: Clinical and Experimental, 2011, 60, 1234-1243.	1.5	51
233	Genetics, genomics, and cancer risk assessment. Ca-A Cancer Journal for Clinicians, 2011, 61, 327-359.	157.7	172
234	BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels. Breast Cancer Research and Treatment, 2011, 130, 1051-1056.	1.1	12

#	Article	IF	Citations
235	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	1.8	18
236	Personalized medicine: new genomics, old lessons. Human Genetics, 2011, 130, 3-14.	1.8	173
237	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
238	Including Additional Controls from Public Databases Improves the Power of a Genome-Wide Association Study. Human Heredity, 2011, 72, 21-34.	0.4	17
239	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	3.0	40
240	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	2.6	91
241	Genetic/Familial High-Risk Assessment: Breast and Ovarian. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 562-594.	2.3	253
242	Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. Breast Cancer Research and Treatment, 2010, 123, 581-585.	1.1	15
243	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
244	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2010, 28, 893-901.	0.8	389
245	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
246	Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer. Cancer Prevention Research, 2010, 3, 611-619.	0.7	60
247	New Pharmacogenomic Paradigm in Breast Cancer Treatment. Journal of Clinical Oncology, 2010, 28, 4665-4666.	0.8	14
248	Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer. Clinical Cancer Research, 2010, 16, 2115-2121.	3.2	263
249	Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genetics, 2010, 6, e1001183.	1.5	85
250	Susceptibility Loci Associated with Prostate Cancer Progression and Mortality. Clinical Cancer Research, 2010, 16, 2819-2832.	3.2	74
251	Diagnosing Hereditary Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, 205-211.	1.0	12
252	Genome-wide Association Studies of Cancer Predisposition. Hematology/Oncology Clinics of North America, 2010, 24, 973-996.	0.9	34

#	Article	IF	Citations
253	Genome-Wide Association Studies of Cancer. Journal of Clinical Oncology, 2010, 28, 4255-4267.	0.8	159
254	Ethicolegal Aspects of Cancer Genetics. Cancer Treatment and Research, 2010, 155, 1-14.	0.2	8
255	Inherited Predisposition to Cancer: Introduction and Overview. Hematology/Oncology Clinics of North America, 2010, 24, 793-797.	0.9	7
256	Breast Cancer Single-Nucleotide Polymorphisms: Statistical Significance and Clinical Utility. Journal of the National Cancer Institute, 2009, 101, 973-975.	3.0	13
257	Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10236-10241.	3.3	62
258	The 6q22.33 Locus and Breast Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2468-2475.	1.1	22
259	BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2009, 27, 433-438.	0.8	194
260	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
261	Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14920-14925.	3.3	59
262	cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 663, 84-89.	0.4	9
263	A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms. Nature Genetics, 2009, 41, 455-459.	9.4	322
264	The Scientific Foundation for Personal Genomics: Recommendations from a National Institutes of Healthâ€“Centers for Disease Control and Prevention Multidisciplinary Workshop. Genetics in Medicine, 2009, 11, 559-567.	1.1	207
265	A Rapid and Reliable Test for BRCA1 and BRCA2 Founder Mutation Analysis in Paraffin Tissue Using Pyrosequencing. Journal of Molecular Diagnostics, 2009, 11, 176-181.	1.2	18
266	Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome. American Journal of Surgical Pathology, 2009, 33, 1639-1645.	2.1	155
267	Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. BMC Genetics, 2008, 9, 14.	2.7	31
268	Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer. Journal of Surgical Oncology, 2008, 97, 621-625.	0.8	9
269	Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Letters, 2008, 270, 173-180.	3.2	19
270	Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4340-4345.	3.3	274

#	Article	IF	Citations
271	Variants of the Adiponectin (<emph type="ital">ADIPOQ</emph>) and Adiponectin Receptor 1 (<emph type="ital">ADIPOR1</emph>) Genes and Colorectal Cancer Risk. JAMA - Journal of the American Medical Association, 2008, 300, 1523.	3.8	127
272	Genomic Profiles for Disease Risk. JAMA - Journal of the American Medical Association, 2008, 299, 1353.	3.8	100
273	Ethical and Legal Implications of Cancer Genetic Testing: Do Physicians Have a Duty to Warn Patients' Relatives About Possible Genetic Risks?. Journal of Oncology Practice, 2008, 4, 229-230.	2.5	18
274	Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology, 2008, 26, 1331-1337.	0.8	522
275	Time to Check CHEK2 in Families With Breast Cancer?. Journal of Clinical Oncology, 2008, 26, 519-520.	0.8	37
276	The Signatures of Autozygosity among Patients with Colorectal Cancer. Cancer Research, 2008, 68, 2610-2621.	0.4	47
277	Variants of the Adiponectin and Adiponectin Receptor 1 Genes and Breast Cancer Risk. Cancer Research, 2008, 68, 3178-3184.	0.4	104
278	Genetic Factors: Hereditary Cancer Predisposition Syndromes. , 2008, , 171-191.		1
279	AURKAF31I Polymorphism and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1416-1421.	1.1	30
280	BRCA Mutations in Women with Ductal Carcinoma In situ. Clinical Cancer Research, 2007, 13, 4306-4310.	3.2	29
281	Modeling Genetic Risk of Breast Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 2637.	3.8	8
282	Single-amplicon MSH2 A636P Mutation Testing in Ashkenazi Jewish Patients With Colorectal Cancer. Annals of Surgery, 2007, 245, 560-565.	2.1	11
283	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	2.6	217
284	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncology, The, 2007, 8, 26-34.	5.1	220
285	Management of an Inherited Predisposition to Breast Cancer. New England Journal of Medicine, 2007, 357, 154-162.	13.9	222
286	The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies. BMC Genetics, 2007, 8, 68.	2.7	8
287	Network modeling links breast cancer susceptibility and centrosome dysfunction. Nature Genetics, 2007, 39, 1338-1349.	9.4	602
288	Ethical and Legal Aspects of Cancer Genetic Testing. Seminars in Oncology, 2007, 34, 435-443.	0.8	28

#	Article	IF	Citations
289	Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis. Annals of Surgical Oncology, 2007, 14, 2510-2518.	0.7	82
290	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2007, 105, 221-228.	1.1	45
291	Spontaneous and therapeutic abortions and the risk of breast cancer among BRCAmutation carriers. Breast Cancer Research, 2006, 8, R15.	2.2	44
292	Cancer Survivorshipâ€"Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations. Journal of the National Cancer Institute, 2006, 98, 15-25.	3.0	295
293	Increased frequency of disease-causing MYH mutations in colon cancer families. Carcinogenesis, 2006, 27, 2243-2249.	1.3	44
294	Cancer Genetic Testing and Assisted Reproduction. Journal of Clinical Oncology, 2006, 24, 4775-4782.	0.8	107
295	MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner. Cancer Research, 2006, 66, 5104-5110.	0.4	277
296	ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes. Annals of Surgical Oncology, 2006, 13, 1296-1321.	0.7	41
297	Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping. Genetic Epidemiology, 2006, 30, 48-61.	0.6	17
298	Tamoxifen and contralateral breast cancer inBRCA1 andBRCA2 carriers: An update. International Journal of Cancer, 2006, 118, 2281-2284.	2.3	246
299	Prediction of Germline Mutations and Cancer Risk in the Lynch Syndrome. JAMA - Journal of the American Medical Association, 2006, 296, 1479.	3.8	328
300	Reducing the Risk of Gynecologic Cancer in the Lynch Syndrome. New England Journal of Medicine, 2006, 354, 293-295.	13.9	34
301	The Role of Prevention in Oncology Practice: Results From a 2004 Survey of American Society of Clinical Oncology Members. Journal of Clinical Oncology, 2006, 24, 2948-2957.	0.8	42
302	Effect of Mammography on Breast Cancer Risk in Women with Mutations in BRCA1 or BRCA2. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2311-2313.	1.1	60
303	Preimplantation Genetic Diagnosis for Cancer Syndromes. JAMA - Journal of the American Medical Association, 2006, 296, 2727.	3.8	77
304	ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes. Journal of Clinical Oncology, 2006, 24, 4642-4660.	0.8	214
305	BRCA Mutation Frequency and Penetrance: New Data, Old Debate. Journal of the National Cancer Institute, 2006, 98, 1675-1677.	3.0	39
306	Genetic/Familial High-Risk Assessment: Breast and Ovarian Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 156.	2.3	46

#	Article	IF	Citations
307	Value of Immunohistochemical Detection of DNA Mismatch Repair Proteins in Predicting Germline Mutation in Hereditary Colorectal Neoplasms. American Journal of Surgical Pathology, 2005, 29, 96-104.	2.1	136
308	Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecologic Oncology, 2005, 96, 21-24.	0.6	35
309	Germline mutations ofAXIN2are not associated with nonsyndromic colorectal cancer. Human Mutation, 2005, 25, 498-500.	1.1	14
310	Colorectal cancer risk in individuals with biallelic or monoallelic mutations ofMYH. International Journal of Cancer, 2005, 114, 505-507.	2.3	56
311	Effect of pregnancy as a risk factor for breast cancer inBRCA1/BRCA2 mutation carriers. International Journal of Cancer, 2005, 117, 988-991.	2.3	152
312	Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations inBRCA1 orBRCA2. Cancer, 2005, 103, 44-51.	2.0	132
313	Ovarian carcinoma screening in women at intermediate risk. Cancer, 2005, 104, 314-320.	2.0	23
314	The TP53 mutational spectrum and frequency of CHEK2*1100delC in Liâ€“Fraumeni-like kindreds. Familial Cancer, 2005, 4, 177-181.	0.9	31
315	Combined Genetic Assessment of Transforming Growth Factor-Î² Signaling Pathway Variants May Predict Breast Cancer Risk. Cancer Research, 2005, 65, 3454-3461.	0.4	83
316	Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families. Journal of the National Cancer Institute, 2005, 97, 1382-1384.	3.0	80
317	Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Human Molecular Genetics, 2005, 14, 555-563.	1.4	109
318	Prevention and Management of Hereditary Breast Cancer. Journal of Clinical Oncology, 2005, 23, 1656-1663.	0.8	152
319	Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study. Journal of Clinical Oncology, 2005, 23, 7491-7496.	0.8	408
320	Hereditary Cancer Predisposition Syndromes. Journal of Clinical Oncology, 2005, 23, 276-292.	0.8	534
321	Frequency of BRCA1 and BRCA2 Mutations in Unselected Ashkenazi Jewish Patients With Colorectal Cancer. Journal of the National Cancer Institute, 2004, 96, 68-70.	3.0	71
322	MSH6 Mutations in Hereditary Nonpolyposis Colon Cancer: Another Slice of the Pie. Journal of Clinical Oncology, 2004, 22, 4449-4451.	0.8	12
323	BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews. Clinical Cancer Research, 2004, 10, 2918-2921.	3.2	156
324	TGFBR1*6A and Cancer: A Meta-Analysis of 12 Case-Control Studies. Journal of Clinical Oncology, 2004, 22, 756-758.	0.8	85

#	Article	IF	Citations
325	Localization of Cancer Susceptibility Genes by Genome-wide Single-Nucleotide Polymorphism Linkage-Disequilibrium Mapping. Cancer Research, 2004, 64, 8116-8125.	0.4	12
326	Breast MRI for Women With Hereditary Cancer Risk. JAMA - Journal of the American Medical Association, 2004, 292, 1368.	3.8	45
327	The "Duty to Warn" a Patient's Family Members About Hereditary Disease Risks. JAMA - Journal of the American Medical Association, 2004, 292, 1469.	3.8	228
328	Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers. Cancer Research, 2004, 64, 5051-5053.	0.4	51
329	A636P testing in Ashkenazi Jews. Familial Cancer, 2004, 3, 223-227.	0.9	7
330	Hereditary ovarian cancer in Ashkenazi Jews. Familial Cancer, 2004, 3, 259-264.	0.9	36
331	The genetics of familial lymphomas. Current Oncology Reports, 2004, 6, 380-387.	1.8	9
332	No major association between TGFBR1*6A and prostate cancer. BMC Genetics, 2004, 5, 28.	2.7	14
333	A636P is associated with early-onset colon cancer in Ashkenazi Jews. Journal of the American College of Surgeons, 2003, 196, 222-225.	0.2	26
334	Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecologic Oncology, 2003, 89, 281-287.	0.6	130
335	Epithelial lesions in prophylactic mastectomy specimens from women withBRCA mutations. Cancer, 2003, 97, 1601-1608.	2.0	90
336	MSH6 germline mutations are rare in colorectal cancer families. International Journal of Cancer, 2003, 107, 571-579.	2.3	53
337	Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients. Leukemia Research, 2003, 27, 841-851.	0.4	16
338	Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Medical Genetics, 2003, 4, 1.	2.1	106
339	A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Research, 2003, 6, R8-R17.	2.2	262
340	BRCA1 and BRCA2 Germline Mutations in Lymphoma Patients. Leukemia and Lymphoma, 2003, 44, 127-131.	0.6	8
341	TGFBR1*6A and Cancer Risk: A Meta-Analysis of Seven Case-Control Studies. Journal of Clinical Oncology, 2003, 21, 3236-3243.	0.8	104
342	Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA Mutations. Journal of Clinical Oncology, 2003, 21, 4222-4227.	0.8	199

#	Article	IF	Citations
343	Shared Genetic Susceptibility to Breast Cancer, Brain Tumors, and Fanconi Anemia. Journal of the National Cancer Institute, 2003, 95, 1548-1551.	3.0	183
344	BLM Heterozygosity and the Risk of Colorectal Cancer. Science, 2002, 297, 2013-2013.	6.0	174
345	Estrogen Receptor-Beta Expression in Hereditary Breast Cancer. Journal of Clinical Oncology, 2002, 20, 3752-3753.	0.8	20
346	Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2002, 94, 1773-1779.	3.0	318
347	Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation. New England Journal of Medicine, 2002, 346, 1609-1615.	13.9	1,363
348	Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers. Journal of Clinical Oncology, 2002, 20, 1260-1268.	0.8	395
349	Considerations in genetic counseling for inherited breast cancer predisposition. Seminars in Radiation Oncology, 2002, 12, 362-370.	1.0	0
350	Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. Genes Chromosomes and Cancer, 2002, 33, 114-122.	1.5	59
351	Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clinical Cancer Research, 2002, 8, 3776-81.	3.2	116
352	Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clinical Cancer Research, 2002, 8, 3813-9.	3.2	29
353	Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1579-85.	1.1	74
354	Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genetics in Medicine, 2001, 3, 422-425.	1.1	17
355	Risk of Endometrial Carcinoma Associated with BRCA Mutation. Gynecologic Oncology, 2001, 80, 395-398.	0.6	147
356	Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens fromBRCA1 heterozygotes. Cancer, 2000, 89, 383-390.	2.0	97
357	Genetic Prognostic Markers for Colorectal Cancer. New England Journal of Medicine, 2000, 342, 124-125.	13.9	25
358	Breast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations. Journal of the National Cancer Institute, 1999, 91, 2112-2117.	3.0	167
359	The APC I1307K allele and breast cancer risk. Nature Genetics, 1998, 20, 13-14.	9.4	65
360	Involvement ofBCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. , 1998, 23, 323-327.		47

#	Article	IF	Citations
361	Haplotype and Phenotype Analysis of Nine Recurrent BRCA2 Mutations in 111 Families: Results of an International Study. American Journal of Human Genetics, 1998, 62, 1381-1388.	2.6	150
362	Chromosomal and Gene Amplification in Diffuse Large B-Cell Lymphoma. Blood, 1998, 92, 234-240.	0.6	308
363	A family with three germline mutations in BRCAl and BRCA2. Clinical Genetics, 1998, 54, 215-218.	1.0	13
364	Familial Hodgkin's and Non-Hodgkin's Lymphoma: Different Patterns in First-Degree Relatives. Leukemia and Lymphoma, 1997, 27, 503-507.	0.6	12
365	New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer. Lancet, The, 1997, 350, 117-118.	6.3	17
366	Prevalence of Recurring BRCA Mutations Among Ashkenazi Jewish Women with Breast Cancer. Genetic Testing and Molecular Biomarkers, 1997, 1, 47-51.	1.7	44
367	Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genetics, 1997, 17, 79-83.	9.4	630
368	Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genetics, 1996, 13, 126-128.	9.4	282
369	Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nature Genetics, 1996, 13, 241-244.	9.4	162
370	The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nature Genetics, 1996, 14, 188-190.	9.4	375
371	BCL6 Gene Rearrangement and Other Cytogenetic Abnormalities in Diffuse Large Cell Lymphoma. Leukemia and Lymphoma, 1995, 20, 85-89.	0.6	30
372	Rearrangement of the bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma. New England Journal of Medicine, 1994, 331, 74-80.	13.9	375
373	Clusters of chromosome 9 aberrations are associated with clinico-pathologic subsets of non-Hodgkin's lymphoma. Genes Chromosomes and Cancer, 1993, 7, 1-7.	1.5	44
374	Chromosome Analysis in the Management of Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1992, 7, 275-282.	0.6	21
375	Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt's type) in American adults: results with treatment designed for acute lymphoblastic leukemia. American Journal of Medicine, 1991, 90, 328-337.	0.6	29
376	Chromosomal Aberrations in Non-Hodgkinâ€™s Lymphoma: Biologic and Clinical Correlations. Hematology/Oncology Clinics of North America, 1991, 5, 853-869.	0.9	64
377	Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: Correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes and Cancer, 1991, 3, 189-201.	1.5	167
378	Clonal cytogenetic abnormalities in Hodgkin's disease. Genes Chromosomes and Cancer, 1991, 3, 294-299.	1.5	36

#	Article	IF	Citations
379	Immunohistochemical, molecular, and cytogenetic analysis of a consecutive series of 20 peripheral t-cell lymphomas and lymphomas of uncertain lineage, including 12 Ki-1 positive lymphomas. Genes Chromosomes and Cancer, 1990, 2, 27-35.	1.5	50
380	18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. British Journal of Haematology, 1989, 72, 178-183.	1.2	97
381	Nonrandom chromosomal aberrations are associated with sites of tissue involvement in non-Hodgkin's lymphoma. Cancer Genetics and Cytogenetics, 1989, 37, 85-93.	1.0	21